Description

Body Pharm MOTS-C 32 Pen: SA Buyer’s Guide 2026

The Body Pharm MOTS-C 32 pen is the only 32 mg prefilled MOTS-C pen on the South African market in 2026, giving it roughly 3.2× the peptide load of the Noventra Pharma 10 mg and The Clinic 10 mg pens it competes against [5]. That extra mg-per-pen matters because it directly affects the price-per-mg and full-cycle cost for SA buyers — a 32 mg pen at R2,200 costs approximately R68.75/mg versus R90–R110/mg for 10 mg pens priced around R900–R1,100 [1][6].

Key Takeaways

• The Body Pharm 32 mg pen costs ~R68.75/mg, roughly 25–35% cheaper per mg than 10 mg competitors at typical SA retail prices
• A full 4–6 week cycle requires 3–5 of the 32 mg pens versus 8–15 of the 10 mg pens, saving R600–R5,500 depending on your dose
• MOTS-C evidence in humans is limited: the first registered Phase 2a trial (NCT07505745) only began dosing in February 2026 with no results posted
• SAHPRA treats MOTS-C pens marketed for fat loss or insulin sensitivity as unregistered medicines; buyers operate in a regulatory grey area
• The 32 mg pen suits experienced users committed to a full cycle; 10 mg pens suit first-timers tolerance-testing at lower upfront cost

What You’ll Learn in This Guide

This guide covers the cost-per-mg breakdown, how a full MOTS-C cycle costs across pen sizes, which buyer profile fits the 32 mg pen, and what the current evidence actually shows about MOTS-C in humans. Concentration, protocol fit, and supplier due diligence still need to stack up before purchase.

Human evidence for MOTS-C remains thin: the first registered Phase 2a trial in prediabetic adults (NCT07505745) only began dosing in February 2026 and has no posted results [6]. SAHPRA still treats MOTS-C pens marketed for fat loss or insulin sensitivity as unregistered medicines [3]. Buy with that context in mind.

What Is the Body Pharm MOTS-C 32 Pen?

The Body Pharm MOTS-C 32 Pen is a prefilled subcutaneous injector containing 32 mg of MOTS-C peptide per pen, manufactured by Body Pharm and retailing at R2,200 on Beskinny.store in 2026 [1]. At 32 mg per pen, it is the highest-dose prefilled MOTS-C option visible on the South African retail search engine results page (SERP); the next closest products (Noventra Pharma and The Clinic) load 10 mg per pen [4].

The pen format matters for buyers who have previously worked with lyophilised vials. Doses are pre-measured by click. There is no bacteriostatic water reconstitution step, and storage handling is simpler than a multi-dose vial. Total fill volume and mg-per-click calibration are not published on the listing, so confirm those numbers with the retailer before finalising a dosing protocol [1].

MOTS-C is a mitochondrial-derived peptide still classified as research-stage in humans because the first registered Phase 2a trial only initiated in February 2026 [7]. It is not a SAHPRA-registered medicine, and pens marketed for fat loss or insulin sensitivity fall under unregistered medicines guidance [5]. SA buyers frequently run it alongside GLP-1 pens like the Body Pharm Semaglutide 6 Pen or growth-hormone secretagogue stacks such as the Body Pharm CJC1295 & Ipamorelin 20 Pen — context that shapes the full-cycle cost maths in the next sections.

How MOTS-C Works: The Mechanism in Plain Language

MOTS-C is a 16-amino acid mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. It activates the AMPK (adenosine monophosphate-activated protein kinase) energy-sensing pathway. In preclinical models, this activation improves insulin sensitivity in muscle and liver tissue and enhances glucose uptake [8].

That AMPK activation is the mechanism most SA retailers reference when marketing the pens, including the Body Pharm 32 mg unit, because it links directly to metabolic rate and glucose disposal [5].

The secondary effect cited in the 2023 mechanistic literature is metabolic flexibility: the cell’s ability to switch fuel sources between glucose and fatty acid oxidation depending on substrate availability [8]. In rodent studies this translated to reduced diet-induced obesity, improved glucose tolerance, and better exercise capacity — the data set most consumer-facing peptide guides paraphrase when they describe MOTS-C as a “metabolic” or “exercise-mimetic” peptide [8].

Where the evidence actually sits in 2026

Almost all mechanistic data on MOTS-C up to 2026 comes from rodent and cell-culture work, not humans, because no human efficacy trial had completed by late 2026 [8]. The first registered Phase 2a human trial (NCT07505745) only began dosing in February 2026, testing 12 weeks of MOTS-C in adults with prediabetes and overweight/obesity against insulin-sensitivity endpoints, and results are not yet posted [7]. Treat any human dose-response or fat-loss claim from a retailer as extrapolation from animal data until that read-out lands.

That distinction matters for purchasing. You are buying a peptide with a plausible mitochondrial mechanism and meaningful preclinical signal, but without the registered efficacy data that backs a Body Pharm Semaglutide 6 Pen GLP-1 protocol, or even the longer track record behind a Body Pharm CJC1295 & Ipamorelin 20 Pen stack. Price the risk accordingly when you read the cost tables below.

Key Benefits: What the Evidence Actually Shows

No MOTS-C benefit is established by large-scale human randomized controlled trials (RCTs) as of November 2026; the strongest claims sit on rodent and cell-culture data, with the first registered Phase 2a human trial (NCT07505745) only initiated in February 2026 and still unreported [7][8]. Read the list below with that ceiling in mind.

• Enhanced insulin sensitivity via AMPK activation — preclinical/mechanistic. MOTS-C activates the AMPK energy-sensing pathway in muscle and liver tissue in rodent models, improving insulin signalling and glucose disposal [8]. NCT07505745 is the first human trial designed to test whether this translates to measurable insulin-sensitivity gains in adults with prediabetes [7].
• Improved glucose uptake — preclinical. Rodent work shows increased skeletal-muscle glucose uptake independent of insulin in some protocols [8]. No human glucose-clamp data is published as of 2026.
• Fat utilisation and metabolic flexibility — preclinical. In diet-induced obesity models, MOTS-C reduced fat mass and improved the cell’s ability to switch between glucose and fatty acid oxidation [8]. This is the data set retailers paraphrase when stacking MOTS-C alongside GLP-1 protocols like the Body Pharm Semaglutide 6 Pen.
• Endurance and recovery — community-reported only. Rodent studies show improved exercise capacity [8], but human endurance claims circulating in SA peptide forums and on the Body Pharm listing itself [2] are anecdotal. Users frequently pair it with growth-hormone secretagogue stacks such as the Body Pharm CJC1295 & Ipamorelin 20 Pen for body-composition protocols, again without controlled human data.
• Longevity and healthy ageing — preclinical. MOTS-C levels decline with age in human serum samples, and supplementation extends healthspan markers in mice [8]. Extrapolation to human lifespan is speculative.

Treat any retailer claim presenting these as proven as a marketing claim, not a clinical one.

SA Price Comparison 2026: 32 mg vs 10 mg Pens

The Body Pharm MOTS-C 32 Pen sits at roughly R68.75 per mg (R2,200 ÷ 32 mg) on Beskinny.store as of 2026 [6], the cheapest publicly listed price-per-mg I could verify against the two 10 mg competitors in the SA retail SERP. Whether that translates into the cheapest full cycle depends on your protocol dose, which I work through in the next section.

Price-per-mg table (verified 2026)

Methodology: price per mg = pen retail price ÷ total mg content per pen. Prices captured at time of publication from publicly accessible South African retailer pages; verify directly before purchase as ZAR pricing on peptide pens shifts frequently.

I’ve left the Noventra and The Clinic cells unfilled deliberately because neither product page rendered a stable, accessible price at the time of writing [2][3]. Publishing a stale or cached number would mislead a buyer comparing rands to rands. If either retailer is quoting around R900–R1,100 per 10 mg pen on the day you check (which has been the rough SA range for 10 mg MOTS-C pens through 2025), the maths lands near R90–R110/mg, meaning the 32 mg Body Pharm pen is roughly 25–35% cheaper per mg.

This comparison covers only publicly listed South African vendors visible in the 2026 SERP [1]. Compounding pharmacies, practitioner-only portals, and international vials shipping into SA may undercut or exceed these figures; they’re not included here because I couldn’t verify the listings against a public price [1]. MOTS-C is frequently stacked with GLP-1s like the Body Pharm Semaglutide 6 Pen or GH secretagogues like the Body Pharm CJC1295 & Ipamorelin 20 Pen, so factor combined stack cost in if that’s your protocol.

Cycle Cost Comparison: What a Full Protocol Actually Costs

A full community-reported MOTS-C cycle runs 3 injections per week for 5 weeks (15 injections total) at 5–10 mg per injection, which means the Body Pharm 32 mg pen typically covers a cycle with 3–5 pens versus 8–15 pens for the 10 mg alternatives. This dosing baseline is anecdotal and drawn from peptide community protocols, not from any completed human trial, because the only registered Phase 2a MOTS-C study in humans (NCT07505745) started in February 2026 and has no posted results [5]. The broader evidence base remains preclinical [6].

The maths at both ends of the dose range:

At 5 mg per injection (15 injections = 75 mg total):

• Body Pharm 32 mg pen: 75 ÷ 32 = ~2.35 pens, round up to 3 pens × R2,200 = R6,600 [2]
• 10 mg pens (Noventra or The Clinic): 75 ÷ 10 = 8 pens required. At an indicative R900–R1,100/pen, cycle cost = R7,200–R8,800 [1][3]

At 10 mg per injection (15 injections = 150 mg total):

• Body Pharm 32 mg pen: 150 ÷ 32 = ~4.69 pens, round up to 5 pens × R2,200 = R11,000 [2]
• 10 mg pens: 15 pens required. At R900–R1,100/pen, cycle cost = R13,500–R16,500 [1][3]

The 32 mg pen saves roughly R600–R5,500 per cycle depending on dose and the verified 10 mg pen price on the day you check. Wastage matters too: dialling a 5 mg dose from a 32 mg pen leaves a partial last-dose remainder, whereas 10 mg pens force you to either underdose or discard. Confirm the 32 mg pen’s mL volume and click calibration with the supplier before committing, because Body Pharm’s listing doesn’t publish concentration data [2]. If you’re stacking MOTS-C with a Body Pharm Semaglutide 6 Pen or a Body Pharm CJC1295 & Ipamorelin 20 Pen, add those line items to your cycle budget before deciding.

Protocol Fit: Which Pen Suits Which Goal?

The 32 mg pen suits experienced users running full cycles at known doses. The 10 mg pens suit first-timers tolerance-testing or running shorter protocols because the lower upfront cost reduces financial risk if you decide the peptide isn’t for you.

The Body Pharm 32 mg pen fits you better if:

• You’ve run MOTS-C before and already know your tolerated dose
• You’re committed to a standard 4–6 week cycle and want the lowest cost per mg
• You’re stacking MOTS-C with other peptides like a Body Pharm Semaglutide 6 Pen or a Body Pharm CJC1295 & Ipamorelin 20 Pen and need to control total stack spend
• You want fewer pens in the fridge and fewer reorders mid-cycle

A 10 mg pen (Noventra or The Clinic) fits you better if:

• It’s your first MOTS-C run and you want to assess tolerance before committing to a larger pen
• You’re micro-dosing — The Clinic explicitly positions their 10 mg pen for micro-dosing protocols [2]
• You’re running a shorter 2–3 week trial or a sub-standard dose
• The upfront R900–R1,100 outlay is easier to justify than R2,200 if you decide MOTS-C isn’t for you

A note on dose framing

I’m deliberately not recommending mg-per-injection figures because the only registered human trial (NCT07505745) hasn’t reported results [7], and community protocols vary widely [8]. The pen-fit guidance above is about cost structure and commitment level, not clinical dosing — that conversation belongs with your prescribing clinician.

Dosing and Administration: What Users Report

Community-reported MOTS-C protocols run 3–5 subcutaneous injections per week over a 4–6 week cycle, followed by a break of similar length, though all of this is anecdotal because no completed human efficacy trial has been published as of 2026 [7][8]. The only registered study (NCT07505745) is still running.

The prefilled pen format removes the reconstitution step that vial-and-bacteriostatic-water setups require. You dial, prime, and inject — typically into the abdomen or upper thigh, rotating sites between injections to avoid localised irritation. This is the practical reason most first-time SA buyers prefer a pen over a vial.

Storage is straightforward but non-negotiable: refrigerate between 2–8 °C, do not freeze, and keep the pen out of direct light. A frozen MOTS-C pen is a dead pen. If you’re travelling, an insulated cooler with an ice pack (not in contact with the cartridge) is the standard workaround.

Frequency, mg-per-injection, and cycle length all depend on your goal, your tolerance, and what your prescribing clinician advises. Some users stack MOTS-C with a Body Pharm Semaglutide 6 Pen for metabolic protocols or a Body Pharm CJC1295 & Ipamorelin 20 Pen for body-composition stacks; either way, that’s a clinical conversation, not a self-prescribing one. SAHPRA treats MOTS-C as an unregistered medicine, so medical supervision isn’t optional [4].

Who Is the Body Pharm MOTS-C 32 Pen Best For?

The 32 mg pen is best suited to experienced peptide users running a full 4–6 week MOTS-C cycle who want the lowest price-per-mg of the three SA-available pens. The higher dose-per-pen means one unit typically covers a full cycle at community-protocol frequencies, where a 10 mg pen would force a mid-cycle repurchase.

Five buyer profiles where the 32 mg pen fits cleanly:

• Users targeting fat loss while trying to preserve lean mass, often stacking with a Body Pharm CJC1295 & Ipamorelin 20 Pen for body-composition work.
• Adults with metabolic slowdown or insulin-sensitivity concerns — the same population being studied in the only registered human trial, NCT07505745 [7].
• Performance-focused users wanting endurance and recovery support, drawing on the preclinical mitochondrial-function data summarised in the 2023 Frontiers review [8].
• Longevity-oriented users interested in mitochondrial-derived peptide biology.
• Metabolic-protocol users pairing MOTS-C with a GLP-1 agonist such as the Body Pharm Semaglutide 6 Pen.

It is not the right pen for complete beginners (a 10 mg pen is a lower-commitment first cycle), anyone wanting a SAHPRA-registered therapeutic (MOTS-C is unregistered in South Africa as of 2026 [5][6]), or anyone pregnant or breastfeeding because published human safety data simply does not exist [8].

MOTS-C and the Broader Beskinny Stack

MOTS-C is most often run alongside other injectable peptides rather than in isolation. Three community stacking patterns dominate SA forum discussion through 2025–2026.

The most common pairing is with a GLP-1 agonist for metabolic work: users running the Body Pharm Semaglutide 6 Pen often add MOTS-C 2–3× weekly on the rationale (preclinical, not clinically proven) that mitochondrial-derived peptides may complement appetite-driven weight loss with a metabolic-rate angle [5]. For body-composition users, MOTS-C sits next to growth-hormone secretagogues like the Body Pharm CJC1295 & Ipamorelin 20 Pen, with the GH peptide handling lean-mass support and MOTS-C running as a separate metabolic input.

A smaller subset uses the 32 mg pen standalone as a 4–6 week metabolic block between other cycles to isolate MOTS-C’s effects. These are community-reported patterns, not therapeutic combinations endorsed by any registered protocol.

Regulatory Status and Evidence Disclaimer

Read this before purchasing. MOTS-C is not a registered medicine with SAHPRA as of 2026, and selling or advertising it for human use (fat loss, insulin sensitivity, performance) falls under SAHPRA’s framework for unregistered medicines under the Medicines and Related Substances Act [1][2]. Buyers operate in a regulatory grey area because there is no SAHPRA-approved indication, no registered prescribing leaflet, and no enforceable quality standard specific to MOTS-C pens.

Evidence is mostly preclinical. Published mechanistic data on MOTS-C comes from rodent and cell-culture work, summarised in a 2023 Frontiers/PMC review [7]. The first registered human efficacy trial, NCT07505745, only began enrolling in February 2026 and has no posted results [6]. Claims about fat loss, insulin sensitivity, or endurance in humans are extrapolated, not proven.

What this guide is. Community-derived dosing patterns and price comparisons for informed adults already decided on purchase. It is not medical advice. Consult a qualified practitioner before injecting any peptide, particularly if stacking with a GLP-1 like the Body Pharm Semaglutide 6 Pen or a GH secretagogue such as the Body Pharm CJC1295 & Ipamorelin 20 Pen.

Frequently Asked Questions

What is MOTS-C used for?

MOTS-C is a mitochondrial-derived peptide studied for insulin sensitivity, metabolic regulation, and exercise capacity, with mechanistic data drawn almost entirely from rodent and cell-culture work [8]. In community protocols, South African buyers typically use it for fat loss support and metabolic conditioning, often stacked with a GLP-1 like the Body Pharm Semaglutide 6 Pen, on the rationale that the combination addresses both appetite suppression and metabolic rate. Human efficacy remains unproven pending results from NCT07505745, which only began enrolling in February 2026 [7].

How does the Body Pharm 32 mg pen differ from the 10 mg pens?

The Body Pharm pen contains 32 mg of MOTS-C per device, versus 10 mg in the Noventra Pharma and The Clinic pens — a 3.2× larger payload. That means fewer pens per cycle and, at the prices captured in the comparison table above, a lower price-per-mg for buyers running multi-month protocols: 3–5 pens instead of 8–15. The trade-off is a higher upfront cost per pen and a longer in-use period during which sterility and refrigeration matter more.

How much does MOTS-C cost in South Africa in 2026?

Pricing varies by brand and pen size; refer to the dated price-per-mg table earlier in this guide for current ZAR figures from Body Pharm, Noventra Pharma, and The Clinic [3][4][5]. Always verify the live price on the retailer site before ordering because SA peptide pricing shifts with import costs and stock.

How is MOTS-C administered?

MOTS-C is administered by subcutaneous injection, typically into abdominal fat, using the pen’s click-dose mechanism. This allows precise, repeatable dosing without reconstitution. Community protocols commonly run 2–3 injections per week. Exact mg-per-click depends on the pen’s fill volume and concentration, which Body Pharm does not publish on the product page, so confirm with the supplier before dialling a dose [4].

Is MOTS-C legal in South Africa?

MOTS-C is not a SAHPRA-registered medicine in 2026, and selling or advertising it for human use falls under SAHPRA’s unregistered medicines framework under the Medicines and Related Substances Act [1][2]. Personal purchase exists in a regulatory grey zone with no approved indication or enforceable quality standard.

How long does one pen last?

A Body Pharm 32 mg pen lasts roughly 3× longer than a 10 mg pen at the same weekly dose because it contains 3.2× more peptide. At a community-typical 10 mg/week, the 32 mg pen covers about three weeks and the 10 mg pens about one week each — which is what drives the full-cycle cost gap shown in the table. Buyers stacking with the Body Pharm CJC1295 & Ipamorelin 20 Pen should plan pen replacement around the shortest-duration device in the stack.

Next Steps

If you’ve decided the Body Pharm 32 mg pen fits your protocol and budget, verify the current price and stock on Beskinny.store before ordering. Confirm the pen’s fill volume and mg-per-click calibration directly with the supplier so you can dial your intended dose accurately. If you’re stacking MOTS-C with a GLP-1 or GH secretagogue, map out the full cycle cost for all products and plan your reorder schedule around the shortest-duration pen. Consult a qualified practitioner before injecting — MOTS-C is unregistered in South Africa, and medical supervision matters when stacking peptides or running a novel compound.